INTRODUCTION
Renal cell carcinoma (RCC) is diagnosed in 273 000 people worldwide annually and results in 116 000 deaths (1) . The prognosis for patients with metastatic RCC (MRCC) has not improved appreciably during the past 25 years. RCC is highly resistant to both chemotherapy and radiation therapy (2) . Immunoreactive cytokines, interferon-a (IFN-a) and interleukin-2 (IL-2) have been used to treat MRCC, but these agents have limited efficacy and are associated with considerable toxic effects. Recently, novel moleculartargeted agents have been developed based on the precise understanding of molecular mechanisms mediating the progression of RCC, and the introduction of these drugs has induced a dramatic paradigm shift in the therapeutic strategy against MRCC (3) .
Sorafenib is an orally active multikinase inhibitor that affects tumor cell proliferation and tumor angiogenesis. It was initially developed as an inhibitor of Raf kinase, but it was found to have broad-spectrum activity against multiple tyrosine kinases, including the vascular endothelial growth factor receptor family (VEGFR-1, -2, -3), the platelet-derived growth factor receptor family (PDGER-b), the stem cell growth factor receptor (c-KIT), Fms-like tyrosine kinase 3 (Flt-3) and the receptor encoded by the RET proto-oncogene (4, 5) .
As with other antineoplastic agents, sorafenib is associated with many adverse events, including diarrhea, hypertension, fatigue and skin toxicities. In a Phase II placebo-controlled randomized discontinuation trial with sorafenib in patients with MRCC, more than 90% experienced dermatologic changes, including hand-foot skin reaction (HFSR), alopecia, stomatitis, facial and scalp erythema and subungual splinter hemorrhages (6) . Skin toxicities such as HFSR are among the frequent adverse events of sorafenib. On the other hand, erythema multiforme (EM) induced by sorafenib has been reported very rarely, and the Stevens -Johnson syndrome and toxic epidermal necrolysis induced by sorafenib have not been reported (7) . However, sorafenib-induced EM may not be very rare. We evaluated cases of EM induced by sorafenib for MRCC.
PATIENTS AND METHODS

PATIENTS
Thirty-six patients with histologically or cytologically confirmed MRCC, who had undergone nephrectomy or biopsy in the primary lesions, were eligible for this study. All patients had measurable disease (by computerized tomography or magnetic resonance imaging), as designated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Previous systemic therapy such as IFN-a, IL-2, sunitinib and everolimus was allowed if completed at least 4 weeks before enrolment. For inclusion in this study, patients were required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or lower; life expectancy of 12 weeks or more; and adequate renal, hepatic and hematological organ function. Patients with nonmalignant systematic disease that precluded them from receiving therapy, including active infection, any clinically significant cardiac arrhythmia and congestive heart failure, were not eligible. Patients with central nerve system metastases, second primary malignant lesions or clinically significant pleural effusions or ascites, or who had used any investigational agent 1 month before enrolment, were not eligible. All patients gave written informed consent before entering this study. This study was approved by the institutional review board at Kitasato University Hospital and conducted in accordance with the Declaration of Helsinki.
STUDY DESIGN
Patients received sorafenib 200 or 400 mg orally, twice daily, at 12 h intervals, on a continuous dosing schedule. All patients were hospitalized for 2 weeks at the beginning of sorafenib treatment. All patients were examined by the urologist or dermatologist every day during hospitalization and received periodic blood tests. Treatment continued on an outpatient basis until disease progression, unacceptable toxicity or death occurred. The dosage was modified when the following criteria were met: hematologic toxicity (Grade 4 neutropenia), skin toxicity (Grade 3 HFSR), hypertension (Grade 4 or uncontrollable) and non-hematologic toxicity (serious or life threatening).
TREATMENT EVALUATION
Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0. Patients who had received at least 1 dose of sorafenib were evaluated for toxicity. Moreover, all patients who had a rash or EM underwent a skin biopsy, and the histopathological diagnosis was confirmed. All patients who experienced EM were examined by a subsequent patch test. The drug was smashed in a mortar and diluted with petrolatum. Dilute concentration was adjusted 0.1, 1 and 10%. The adjusted drug was fixed on a back of the patient with a hypoallergic tape for 48 h. Reading was done after 48 and 72 h (8) .
RESULTS
PATIENT CHARACTERISTICS
Between November 2006 and November 2011, 36 patients were enrolled in this study and received at least 1 dose of sorafenib for MRCC. The clinical characteristics of all patients are listed in Table 1 . Of the 36 patients, 26 (72%) were men and 10 (28%) were women, with a median age of 67 years (range, 41 -79 years). Twenty-seven patients (75%) had clear cell carcinoma and 9 (25%) had non-clear cell carcinoma. Twenty-eight patients (78%) had undergone radical nephrectomy and 26 (72%) had received systemic therapy such as IFN-a, IL-2, sunitinib and everolimus. Ten patients (28%) received sorafenib as the first-line treatment. The median sorafenib treatment duration was 114 days (range, 5 -1282 days).
SKIN TOXICITY
A total of 36 patients who had received at least 1 dose of sorafenib treatment were evaluated for adverse events analysis. Skin toxicity of sorafenib was demonstrated in 28 (78%) patients, as defined by NCI-CTCAE v3.0. HFSR occurred in 17 patients (47%), EM in 9 (25%) (Fig. 1) , rash/ desquamation in 6 (17%) and alopecia in 9 (25%) ( Table 2 ). Figure 2 shows the time course of EM rates after administration of sorafenib. The median duration of EM was 10 days (range, 5 -20 days). Skin biopsy was performed and histopathological diagnosis was confirmed in all nine patients who experienced EM (Fig. 3) . All nine showed a positive Jpn J Clin Oncol 2012;42 (9) 821 reaction to sorafenib on the subsequent patch test. Characteristics of the EM and non-EM cohorts are summarized in Table 1 . There were no significant differences between the EM group and the non-EM group (Table 1) .
DISCUSSION
Recent introduction of novel targeted molecular therapy has resulted in a dramatic paradigm shift in the therapeutic strategy for MRCC (3) . Sorafenib was originally indentified as an inhibitor of Raf kinase but was subsequently found to strongly cross-react with VEGFR-1, -2, -3, PDGER-b and c-KIT (5). Most importantly, the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study reported a doubling of progression-free survival from 2.8 to 5.5 months with active treatment (4). Unlike conventional anticancer drugs, sorafenib is associated with many adverse events, such as diarrhea, hypertension and HFSR. Skin toxicities of sorafenib are very common, affecting 91% of the patients in the subsidiary study performed by Autier et al. (9) . However, these skin toxicities are generally manageable. Table 2 compares the skin toxicities of sorafenib observed in the present study, the Phase III TARGET study and a Japanese Phase II. The TARGET study reported that EM occurred in 2.4% of the patients, and the Japanese Phase II study reported that EM occurred in 1.5% of the patients (4, 10). There have been only a few reports about sorafenib-induced EM (7, 11, 12) . Therefore, EM induced by sorafenib is thought to be very rare. However, rash/desquamation occurred in 40%. This may include the relatively mild EM cases, in which a skin biopsy and patch test were not performed. EM is a well-recognized manifestation of 
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Erythema multiforme induced by sorafenib drug toxicity, although in a prospective study of EM, only 10% of the cases were drug-related (13) . In another study, prior medication, especially cephalosporins, was recorded in 59% of EM patients (14) . Kodaira et al. (15) also reported that 3 (19%) of 16 RCC patients experienced EM induced by sorafenib. In the present study, EM induced by sorafenib occurred in nine (25%) patients. A skin biopsy was performed in all patients who experienced EM, and the histopathological diagnosis was confirmed. In addition, the patch test for sorafenib was positive in all patients. Therefore, re-administration of sorafenib was contraindicated. Although, the sorafenib patch test was not applied to healthy controls. It may be possible that these positive skin reactions were induced by a primary irritant mechanism but not by an allergy to the reagent. Among the nine patients, sunitinib was administered to five as a next-line treatment, but EM did not occur in five. Although six patients who experienced rash were administered a reduced dose of sorafenib, they did not all have the same rash. Those skin toxicities were diagnosed as non-allergic toxicoderma. The rate of EM may be different for Japanese and Caucasians. Sorafenib-induced EM may not be very rare in Japanese patients. Drugs and viral infection are the main causes of toxic eruptions. Drug-induced eruptions are classified as allergic or non-allergic. HFSR is reported in a majority of patients who have received sorafenib treatment. It is a dosedependent and non-allergic mechanism (16 -18) . On the other hand, EM is considered to be a Type IV allergy. Generally, sorafenib cannot be re-administered for the patient who has experienced EM. In this study, patch test results for sorafenib were positive in all patients. MacGregor et al. (7) reported that a patient who experienced EM was rechallenged with a reduced dose of sorafenib (100 mg) but developed the same eruption within 24 h. Confirmation of drug sensitivity necessitates re-exposure to the drug, which may carry an unacceptable risk.
EM involves macular, papular or urticarial lesions, as well as the classic iris or target lesions, distributed preferentially on the distal extremities, and may involve the palms or trunk. The lesions are dull red, flat or slightly raised maculopapules that may remain small or may reach a diameter of 1-3 cm in 48 h. Target lesions are ,3 cm in diameter and round and have three zones: a central area of dusky erythema or purpura; a middle, paler zone of edema and an outer ring of erythema with a well-defined edge. In histopathological examinations, the most important changes are in the upper dermis and lower epidermis. Some cases have prominent dermal inflammatory changes, with a lymphohistiocytic infiltrate rich in T lymphocytes around blood change. There may also be vacuolar degeneration of the lower epidermis or individual necrotic epidermal cells (19) .
Several studies have reported an association between the antitumor efficacy of molecular-targeted agents and skin toxicity. Interestingly, response as a function of skin toxicity has been reported in the literature for the selective epidermal growth factor receptor (EGFR) inhibitors used for the treatment of other solid tumors. In the National Cancer Institute of Canada Clinical Trials Group Study BR.21, Wacker et al. (20) reported an association between development of rash and efficacy of erlotinib for non -small cell lung cancer. Patients who developed grade 1 rash survived 144% longer than patients who did not develop rash (HR, 0.41; 95% CI, 0.31 -0.55; P , 0.001), and patients with grade 2 rash survived 245% longer than patients who did not develop rash (HR, 0.29; 95% CI, 0.22 -0.38; P , 0.001). Similar results were observed for progression-free survival. A similar relationship between rash and clinical outcomes was noted in studies of panitumumab, an EGFR monoclonal antibody (21) . One of the main targets of sorafenib is Raf kinase, which is a downstream effector molecule of the EGFR signalling pathway. Strumberg et al. (22) reported that patients experiencing toxic effects of sorafenib (300 -600 mg twice a day) in the skin had a significantly longer time to progression than patients without toxic effects in the skin. Appearance of more severe rash has been associated with better treatment outcomes. It is important to continue molecular-targeted therapy while treating any non-allergic skin reaction, such as rash. However, patients who experience EM induced by sorafenib cannot continue sorafenib, because the EM is an allergic mechanism.
Limitations of this study are that adverse event data for sorafenib treatment were evaluated retrospectively, and the sample size is small. Although our analysis relied on a small sample size, nine patients (25%) who were treated with sorafenib had EM. All patients who experienced EM had a skin biopsy, and the histopathological diagnosis was confirmed. The rate of sorafenib-induced EM we observed may have been higher than previously reported because a dermatologist was consulted when sorafenib was initiated. The molecular mechanism of this type of toxicity remains unknown. We will study many more cases in the future and will investigate this discrepancy between the rate of EM in Japanese and Caucasians. Further investigation is necessary to elucidate the mechanism of sorafenib-induced EM and identify an effective treatment strategy.
CONCLUSIONS
EM induced by sorafenib may not be a very rare adverse event in Japanese patients. Patients who once showed EM after sorafenib treatment are never to be treated with sorafenib again. Sorafenib is one of a few standard agents for treating MRCC. Patients treated with sorafenib should be monitored very carefully, with a multidisciplinary approach. Consultation with a dermatologist is critical because some cases quickly become severe.
